Results 171 to 180 of about 3,353 (184)

In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019

Diagnostic Microbiology and Infectious Disease, 2021
Alyssa Golden, James Karlowsky
exaly  

Summary of opinion: Recarbrio,imipenem / cilastatin / relebactam

Case Medical Research, 2019
openaire   +2 more sources

Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo-β-lactamase-producing enterobacterales

Diagnostic Microbiology and Infectious Disease, 2022
Mark Biagi, Rodrigo Mendes, Lalitagauri Deshpande   +2 more
exaly  

Derivatives of relebactam and uses thereof

2020
GORDON ERIC, DUNCTON MATTHEW, FREUND JOHN   +2 more
openaire   +2 more sources

Relebactam. Beta-lactamase inhibitor

Drugs of the Future, 2015
openaire   +1 more source

Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants

Antimicrobial Agents and Chemotherapy, 2020
José A Oteo, Maria Nieves Larrosa, Antonio Oliver   +2 more
exaly  

Effect of Porins and bla KPC Expression on Activity of Imipenem with Relebactam in Klebsiella pneumoniae : Can Antibiotic Combinations Overcome Resistance?

Microbial Drug Resistance, 2018
John Quale, David Landman
exaly  

In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy, 2020
Bartolome Moya, Antonio Oliver, Carlos Juan   +2 more
exaly  

Imipenem-Relebactam Pharmacokinetics in Augmented Renal Clearance

Case Medical Research, 2019
openaire   +1 more source

Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015–17

Journal of Antimicrobial Chemotherapy, 2019
Katherine Young, James Karlowsky, Sibylle Lob   +2 more
exaly